Phase I trial of CB 008 in patients with Ebola virus infections in West Africa

Trial Profile

Phase I trial of CB 008 in patients with Ebola virus infections in West Africa

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs CB 008 (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors Canopus BioPharma
  • Most Recent Events

    • 22 Jan 2015 New trial record
    • 19 Dec 2014 This trial in West Africa is expected to be initiated after an Ebola study in primates, according to a Canopus BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top